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Introduction: Localized involutional lipoatrophy of subcutaneous adipose tissue may develop due to subcutaneous
injection of pharmaceutical preparations. The pathogenesis of this adverse drug reaction is unknown. The
progression of localized involutional lipoatrophy ceases and occasionally it resolves after withdrawing the inducing
agent. In case of localized involutional lipoatrophy due to subcutaneous insulin therapy, low-dose systemic
corticosteroids may be curative despite ongoing insulin administration.
Case presentation: We report a recurrence of insulin-induced localized involutional lipoatrophy at the abdominal
wall in a 57-year-old Caucasian woman with type-1 diabetes on continuous subcutaneous insulin infusion. The first
episode of insulin-induced localized involutional lipoatrophy two years previously had been cured by oral prednisone.
The recurrence was treated immediately with 10mg prednisone once daily for five months, and was cured thereafter.
The insulin analog preparation (Humalog™) and the insulin pump equipment (Accu-Chek Spirit™) applied were the
same during both episodes. Both episodes were preceded by a temporary disturbance of the immune balance (the first
episode by vaccination, the second episode through shingles).
Conclusions: This case confirms that insulin-induced localized involutional lipoatrophy in type-1 diabetes can occur
again, and can be cured by systemic corticosteroids. We suggest that temporary disturbance of the immune balance
may trigger this transitory idiosyncratic reaction in a susceptible individual.Introduction
Localized involutional lipoatrophy (LIL) of subcutaneous
adipose tissue is a rare condition, characterized by re-
duction of fat cells in size, and, occasionally, in number.
The fat tissue involution develops without symptomatic
inflammation, although histopathology of incipient cases
may reveal few inflammatory cells among the atrophic
fat tissue. Muscle tissue is never involved.
Lopez et al. [1] have obtained biopsies of lipoatrophies
in three patients shortly after the last insulin injection;
histopathology showed some lymphocytic, eosinophilic, and
mast cell infiltration. However, direct immunofluorescence
for immunoglobulin G (IgG), for immunoglobulin A (IgA),
immunoglobulin M (IgM), complement component 3 (C3)
and fibrin could not be demonstrated [1], in line with other
authors [2]. Adipose tissue was atrophied, with focal fibro-
sis [1]. Adipocytes were shrunk and reduced in number,* Correspondence: chantelau@gmx.de
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unless otherwise stated.consistent with previous reports [3-5]. Milan et al. [6]
provided ultrastructural analyses on chronic lipoatrophies,
having existed for eight months to six years (median 26
months) in three patients using Humalog™. They showed
fat cell atrophy, deposition of amyloid, and numerous pe-
rivascular preadipocytes. Quantitative polymerase chain re-
action revealed a reduction in adipocyte-specific messenger
ribonucleic acid (mRNA) (perilipin, adiponectin, fatty
acid-binding protein 4, peroxisome proliferator-activated
receptor gamma 2), whereas mRNA of adipocyte enhancer-
binding protein 1 was enhanced, and of leptin was reduced
to zero [6]. There was no evidence of inflammation. Rather,
the histopathologic pattern was like that of fat tissue
undergoing starvation, except for the amyloid deposition,
that is conglomerates of denaturated exogenous insulin or
insulin analog [7].
The etiopathogenesis of the LIL is unknown; it is associ-
ated with various immunological disorders (for example
type-1 diabetes mellitus, immunogenic thyreopathies) and
has a female preponderance. LIL is probably idiopathic,
but develops predominantly after local mechanical traumatral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ample insulin, antibiotics, vaccines, corticosteroids, growth
hormone). The drug-induced type of LIL stops spreading
after withdrawal of the agent. In children, insulin-induced
LIL may resolve spontaneously after changing the insulin
brand [8].
We have recently reported on a patient with incipient
LIL induced by external insulin pump therapy with
Humalog™ [5]. Within 10 months of low-dose oral pred-
nisone treatment, the LIL resolved completely. We now
report another episode of LIL in the same patient, at an
insulin infusion site close to a previously lipoatrophic area.
Case presentation
Our patient is a 57-year-old Caucasian woman born in
1956 and diagnosed with type-1 diabetes mellitus in 1969.
At the time of writing this report, in March 2014, she is
still free from significant diabetic retinopathy, nephropa-
thy, and neuropathy. She has been treated with an insulin
pump since 1984, and has been using a U-100 analog
insulin lispro (Humalog™, Eli Lilly Deutschland, Bad
Homburg, Germany) since 2004. The equipment applied
from 2008 onward comprised an Accu-Chek Spirit™ insu-
lin pump and Accu-Chek FlexLink™ infusion sets with
8mm steel cannula (all from Roche Diabetes Care, Burg-
dorf, Switzerland). The cannula part of the infusion set
was changed every two days, and the tubing (60cm long)
was changed every 10 days, together with the insulin
reservoir inside the pump. The dose of Humalog™ was
around 25 to 30 units/day. Apart from Humalog™, her
current medication consists of levothyroxine 125μg once
daily because of immunogenic thyroid atrophy. Her most
recent glycated hemoglobin (HbA1c) test result (normal
range 4 to 6 percent of total hemoglobin) was 6.3 percent,
and her body mass index was 23 to 24kg/m2.Figure 1 Development of localized involutional lipoatrophy at the ins
with oral prednisone (10 mg/day from 15 April 2012 to 26 June 2012
2012 until December 2012.Following a hepatitis vaccination with Twinrix™
(GlaxoSmithKline Dresden, Germany), in 2007 and 2008,
our patient had experienced a first episode of LIL at the
Humalog™ infusion sites on both sides of the umbilicus.
The lipoatrophic defects were cured by low-dose oral
prednisone therapy from 2009 to 2010, as we published in
2011 [5]. After a prolonged cold between December 2011
and January 2012, herpes zoster (shingles) broke out at the
left thoracolumbar region (T 10 dermatome), and healed
uneventfully in February 2012. Shortly thereafter, in
March 2012, a solitary spot of subcutaneous fat atrophy
was noticed at one catheter insertion site on the abdom-
inal wall left of the umbilicus (Figure 1), and was diag-
nosed as LIL recurrence.
Laboratory tests were limited to determinations of
varicella-zoster virus (VZV) IgG-antibody titer (3230mIU/
ml; enzyme-linked immunosorbent assay (ELISA), nor-
mal <149mIU/ml), VZV IgM negative; herpes simplex virus
IgG-antibody titer (7 IU; normal <0.9 IU), human leukocyte
antigen (HLA)-Cw7 (positive), HLA-Cw6 (negative), HLA-
B27 (negative), HLA-DR4 (negative), and HLA-DRB1*03
allele (positive). Other markers of autoimmune diseases
(like antinuclear antibodies (ANA), antinuclear cytoplas-
matic antibodies (ANCA)) had previously been found nega-
tive [5]. Because of the limited information gained from
biopsies during the first episode of LIL [5], biopsies were
not repeated on this occasion.
It was decided to carry on with the insulin preparation
(Humalog™) and the pump equipment unchanged, at
variance to the first LIL episode. Oral prednisone ther-
apy was initiated by mid-April 2012, when the atrophic
area was still relatively small (approximately 3cm in
diameter, see Figure 1). The starting dose was 10mg/day,
which was reduced deliberately to 5mg/day after nine
weeks (the end of June 2012), and discontinued by theulin infusion site before (15 April 2012) and during treatment
, 5 mg/day until 21 August 2012). No prednisone from 22 August
Chantelau et al. Journal of Medical Case Reports 2014, 8:223 Page 3 of 5
http://www.jmedicalcasereports.com/content/8/1/223end of August 2012. The reasons for discontinuation
were intolerable emotional disturbances and blood glu-
cose instability, attributed to prednisone. At that time
point, the lipoatrophy had improved (see Figure 1) but
the excavation was not entirely refilled. There were no
new lipoatrophic sites. By the end of December 2012,
prednisone 10mg/day was resumed in order to improve
the remaining lipoatrophy (Figure 2), and was tapered
off by the end of March 2013, because the lipoatrophy
was almost cured. The total duration of 10mg prednis-
one daily was 20 weeks (five months). In March 2014,
the LIL was still in remission.
Discussion
The present case confirms the effectiveness of 10mg pred-
nisone orally once daily to cure an incipient insulin-
induced LIL, localized at a Humalog™ infusion site, under
conditions of ongoing subcutaneous Humalog™ applica-
tion elsewhere at the abdomen. In contrast to a previous
LIL episode in the same patient [5], prednisone treatment
was required for only five months altogether, most likely
because it was started early after the onset of the LIL when
the defect was relatively small. The first episode of LIL
had produced lipoatrophic defects which were more than
twice as large (6×7cm) as the present one. They had
existed already for up to 11 months before treatment was
initiated and, hence, required prednisone for 10 months
for complete resolution.
The etiopathogenesis of insulin-induced LIL is un-
known. In our case, the mechanical needle trauma or the
injected agent (Humalog™) potentially could have played a
role, as both had been continued since the first LIL epi-
sode. The importance of the injected agent is emphasizedFigure 2 Development of localized involutional lipoatrophy at the ins
resumption of 10mg prednisone daily (the end of December 2012 to
from 25 March 2013 until 31 December 2013.by a previous placebo-controlled study of pegylated growth
hormone [9]. While 13 percent of patients injecting pegy-
lated growth hormone developed LIL, none of the patients
injecting a placebo (containing the same components as
the verum, except for the pegylated growth hormone, that
is water, sodium phosphate, mannitol and glycine) did. The
LIL resolved spontaneously within two to three months
after cessation of the growth hormone preparation [9].
Likewise, insulin-induced LIL in a type-2 diabetic patient
resolved spontaneously within six months after cessation
of any insulin treatment [10].
In our patient it was not possible to stop the administra-
tion of insulin by subcutaneous route. Changing the insu-
lin brand had proved ineffective previously [5]. Hence, we
resorted to drug treatment by oral prednisone, as in the
first LIL episode two years ago [5]. The effective dose
was 10mg daily; 5mg/day was presumably not enough
(see Figures 1, 2). Glucocorticoids have proved effective in
other cases of incipient insulin-induced LIL [5,11-13];
however, the pathophysiological basis of the effectiveness
remains to be determined. Is it the anti-inflammatory ef-
fect [14]? In our case, the incipient LIL did not appear in-
flamed (see Figures 1, 2). Is it the corticoid effect on fat
cell differentiation? Hauner et al. [15] have demonstrated
in vitro that glucocorticosteroids and insulin stimulate the
differentiation of adipocytes from preadipocytes and their
enlarging.
Similar to the first episode of LIL, which was preceded
by a hepatitis vaccination, the second one was also pre-
ceded by an affection of the immune system, as evidenced
by a herpes zoster rash four weeks before. Parallels may be
drawn to infectious mononucleosis, an infection by an-
other herpes virus (Epstein-Barr virus), which triggers anulin infusion site, before (2 December 2012) and after
mid-March 2013, tapered off until 24 March 2013). No prednisone
Chantelau et al. Journal of Medical Case Reports 2014, 8:223 Page 4 of 5
http://www.jmedicalcasereports.com/content/8/1/223adverse drug reaction (exanthema) to ampicilline in sus-
ceptible patients [16,17]. Unfortunately, previous reports
on insulin-induced LIL have never considered the possi-
bility that certain intercurrent illnesses or disturbances of
the immune system may have instigated the onset of the
condition.
The signal for the drug reaction (fat tissue involution) in
our case most likely originated from an interaction of the
subcutaneously administered insulin lispro with some un-
known transient immunologic (or other) idiosyncratic trig-
ger. Idiosyncrasy, however, implies individual susceptibility
[18]. Consistent with this theory, four other insulin-treated
diabetic patients with herpes zoster, two of whom with sig-
nificant thyroid autoimmunity [19], never exhibited LIL
(see Table 1). They probably lack the specific susceptibility
(E.A.C., unpublished).
Various subcutaneously administered pharmaceuticals
including hormone preparations [1-6,8-13,20,21] and vac-
cines [22] may be the cause of LIL. In cases of incipient
insulin-induced LIL, the idiosyncratic trigger can obviously
be turned off by systemic corticosteroid application, des-
pite ongoing subcutaneous insulin administration. More-
over, corticosteroid treatment may help the atrophied fat
tissue to regenerate. It remains to be demonstrated if corti-
costeroids are of similar effectiveness in other phases and
types of LIL.
Conclusions
The present case demonstrates the favorable outcome of
insulin lispro (Humalog™) associated localized involutionalTable 1 Clinical features of four diabetic patients with
known history of herpes zoster, who never exhibited
insulin-induced localized involutional lipoatrophy (LIL)
Zoster patients without insulin-induced LIL
Gender male female male female
Age, years 56 60 59 79
Type of diabetes type-1 type-1 type-1 type-2
Duration of diabetes, years 37 36 28 19
Diabetic complications1 none none none none
Insulin therapy injections injections CSII2 injections
Application of Humalog™ no no no no
Varicella-zoster IgG, mU/ml* 1400 >2000 1400 >2000
Varicella-zoster IgM* negative negative negative negative
HbA1c, % 7.6 7.1 7.1 8.9
Postherpetic neuralgia yes yes no no
Other relevant features yes3 yes4 yes5 yes6
1Neuropathy, retinopathy, nephropathy; 2continuous subcutaneous insulin
infusion with external insulin pump; 3insulin lipohypertrophy: lipoma with
focal fibrosis and amyloid deposition (histologically proven); 4thyroid
autoantibody positive, 5immunogenic thyroid atrophy; 6multiple allergies;
*ELISA, enzyme-linked immunosorbent assay. CSII, continuous subcutaneous
insulin infusion; IgG, immunoglobulin G; IgM, immunoglobulin M; HbA1c,
glycated hemoglobin.lipoatrophy (LIL), which was treated early after its incep-
tion with low-dose prednisone. Of note, the LIL was a re-
currence, and the present and the previous episode had
been preceded by acute disturbances of the immune sys-
tem. These observations lend support to the hypothesis
that insulin-induced LIL may be a transitory idiosyncrasy.
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